Core Insights - Immatics N.V. has appointed Dr. Alise Reicin to its Board of Directors, bringing extensive experience in the pharmaceutical industry and a history of developing significant therapies like Keytruda® [1][2][3] - Dr. Reicin's leadership is expected to enhance Immatics' efforts in advancing TCR-based therapies for solid tumors, addressing unmet medical needs in cancer treatment [2][8] Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on discovering and developing T cell-redirecting cancer immunotherapies, with a pipeline that includes Adoptive Cell Therapies and TCR Bispecifics [4] - The company aims to enable robust T cell responses against cancer targets, leveraging partnerships with global pharmaceutical leaders [4] Leadership Experience - Dr. Reicin has held key positions in various pharmaceutical companies, including President of Global Clinical Development at Celgene and Senior Vice President at EMD Serono, contributing to the approval of multiple drugs [3] - Under her leadership at Tectonic Therapeutic, the company completed an $80 million Series A financing and advanced its first asset into clinical trials [3] Future Outlook - Dr. Reicin's appointment is set to continue through the Company's Annual General Meeting in 2025, indicating a long-term commitment to guiding Immatics' strategic direction [9] - The company is at a dynamic stage of development, particularly with its lead cell therapy candidate, ACTengine® IMA203, showing promising results in advanced metastatic melanoma patients [8]
Immatics Appoints Alise Reicin to Board of Directors